CNR2 and neoplasm: Taken together, these data suggest that endogenous CB2 activation suppresses colon cancer development by altering the balance between pro-tumorigenic and anti-tumorigenic immune cells in the spleen, and by reducing the levels of immunosuppressive factors in the tumor-microenvironment.